Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Randomized, Multi-Center, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety, Immunogenicity and Potential Efficacy of an rVSV-SARS-CoV-2-S Vaccine (IIBR-100) in Adults

NCT04608305 is registered in ClinicalTrials.gov with Israel Institute for Biological Research (IIBR) as lead sponsor.

NCT NCT04608305
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04608305 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Randomized, Multi-Center, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety, Immunogenicity and Potential Efficacy of an rVSV-SARS-CoV-2-S Vaccine (IIBR-100) in Adults
Lead sponsor
Israel Institute for Biological Research (IIBR)
Phase
Phase 1/2
Overall status
Completed
Start date
October 28, 2020
Completion date
October 3, 2022
Enrollment
843 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

covid19